Oculos and Optceutics Partner to Serve Ophthalmic, R&D Solutions

Optceutics

Strategic collaboration provides services to early spanning clients

Leading vertically-integrated ophthalmic R&D organization, Oculos and a leading expert in ophthalmic R&D and the developer of the PK-EyeTM , Optceutics, announced to enter into a co-promotion arrangement to provide broader services for clients spanning from early research through product approval.

The co-promotion agreement demonstrates the commitment by both organizations to providing a seamless engagement to ophthalmic companies looking for support across the entire R&D lifecycle.

The upcoming long 5 days event from April 28 – May 2, 2019, Optceutics will join Oculos at booth #1455 on the occasion of the Association of Research in Vision and Ophthalmology (ARVO) Annual Meeting in Vancouver, British Columbia.

Optceutics and its vitromodel of the human eye

London based Optceutics uses a dynamic ophthalmic pharmacokinetic model, PK-Eye™, to speed and enhance the development of intravitreal injection and implant based biologic and pharmaceutical products. The PK-Eye™ is used to identify the right formulation technology, optimize the selection of dose and dose frequency, compare activity and duration to known products, reduce program risk before moving into costly animal and human studies, speed development of biosimilar products and generate unique data to support additional patent coverage.

Chris Redhead, CEO of Optceutics commented, “Oculos has a well-deserved reputation as a leading provider of ophthalmic drug R&D. We believe access to its expanding repertoire of preclinical, clinical and regulatory expertise will have huge benefits for our clients moving their new drugs and formulations towards the market.”

Oculos provides integrated insights

Operating out of Rush, NY and Tampa, Florida, Oculos’ fully integrated ophthalmic R&D organization provides services in the following areas for ophthalmic pharmaceutical, biotech and medical device companies across the globe: regulatory strategy / submission, formulation development, analytical chemistry, microbiology, CMC and clinical research. The organization stands to improve the quality of life for patients and consumers by supporting the research, development and clinical testing of life-enhancing ophthalmic products.

Ben Burton, President and CEO of Oculos, stated, “We are excited about expanding our relationship with Optceutics, and the opportunity it brings to serve even more clients across the ophthalmic pharmaceutical and device continuum.  We know Chris and the team well and are impressed with their scientific acumen and client-centered approach. We look forward to bringing this extension of services to our clients.”